Allay Therapeutics’ Phase 2B Clinical Study Supports Ability of ATX101 To Deliver Four Weeks of Sustained Post-surgical Pain Relief
Allay Announces Development Agreement with Maruishi
Allay Therapeutics Appoints Nicole Vitullo to Board of Directors
Allay Therapeutics has added a new name to its star-studded investor syndicate: Evonik. The specialty chemicals company backed the startup after seeing promise in drug delivery technology that is enabled by its biodegradable polymers.
MENLO PARK, Calif.--(BUSINESS WIRE)--Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the appointment of Ron Burch, M.D., Ph.D. to its Scientific Advisory Board. Dr. Burch brings significant experience in the development and commercialization of drug delivery and pain management therapeutics.
Backed by a treatment-tuning platform, Allay Therapeutics is giving pain relief a major upgrade. Rather than relying on drugs repeatedly administered by capsule or IV to find their way to the point of pain, Allay’s analgesics are implanted directly into the surgical site and, thanks to slow-dissolving biopolymers, can provide post-op relief for several weeks.
MENLO PARK, Calif.--(BUSINESS WIRE)--Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the completion of its oversubscribed $60M Series C financing, led by Arboretum Ventures. Participating in the round were NEA, Temasek, Pavilion Capital, Brandon Capital Partners, Vertex Growth, Vertex Ventures HC and WTT Investment Ltd. The proceeds from the Series C will advance the Company’s lead candidate, ATX-101, into Phase 2b clinical trials, and support the further development of Allay’s platform for ultra-sustained analgesic products.
Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the appointment of David Hewitt, M.D. as chief medical officer. Dr. Hewitt is an accomplished neurologist and clinical trialist with over two decades of experience in clinical development and medical affairs. He joins Allay from Nura Bio, where he served as senior vice president, clinical development.